Form 4: Neogenomics Director Lynn Tetrault Trades Shares

Neogenomics Inc. Director Lynn Tetrault reported a transaction involving the acquisition of 5,307 shares of common stock.

Summary

• Director Lynn Tetrault acquired 5,307 shares of Neogenomics Inc. common stock on June 9, 2026, at a price of $11.29 per share.
• Following this transaction, Tetrault directly beneficially owns 91,422 shares of common stock.
• Additionally, Tetrault indirectly beneficially owns 7,000 shares through the Lynn Tetrault Rollover IRA.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine insider transaction without providing new financial or strategic information that would significantly alter the investment thesis.

Positives

• Director Lynn Tetrault's acquisition of company stock can be interpreted as a positive signal of confidence in the company's future prospects.
• The acquisition of 5,307 shares at $11.29 per share indicates a belief in the current valuation or potential for growth.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a transaction of securities.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are closely watched by the market as they can provide insights into management's perception of the company's value and future prospects.

Stakeholder Impact

• Shareholders may view the director's purchase of stock positively, interpreting it as a sign of confidence in the company's future performance.

Key Dates

Keywords

Neogenomics Inc., NEO, Form 4, Insider Trading, Director Transaction, Common Stock, Beneficial Ownership